Hervé R Bonnefoi

9PUBLICATIONS
71CO-AUTHORS
Tumour immunologyPredictive and prognostic markersEnvironmental epidemiologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jan 18, 2024
Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial.

Ian E Krop, Lorenza Mittempergher, Joseph N Paulson

|Apr 19, 2023
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

Marion T van Mackelenbergh, Sibylle Loibl, Michael Untch

|Mar 28, 2023
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy.

Pierre Squifflet, Everardo D Saad, Sibylle Loibl

|Dec 15, 2022
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.

Olivia Pagani, Barbara A Walley, Gini F Fleming

|Dec 09, 2022
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.

Prudence A Francis, Gini F Fleming, István Láng

|Dec 10, 2021
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.

Ian E Krop, Seock-Ah Im, Carlos Barrios

Pageof 2

Frequent Collaborators

5 joint publications

Richard Gelber

5 joint publications

Sibylle Loibl

4 joint publications

Martine Piccart

4 joint publications

Marco Colleoni